(Q44630293)

4 December 2017

title

A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines (English)

1 reference

4 December 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21075267

26 August 2024

1

Sandra E. Talbird

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21075267

26 August 2024

author name string

Afisi S. Ismaila

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21075267

26 August 2024

Thomas N. Taylor

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21075267

26 August 2024

language of work or name

English

0 references

publication date

1 November 2010

1 reference

4 December 2017

19 November 2010

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21075267

full work available at URL

26 August 2024

https://api.elsevier.com/content/article/PII:S0264410X1000811X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2010.06.013

https://api.elsevier.com/content/article/PII:S0264410X1000811X?httpAccept=text/plain

26 August 2024

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2010.06.013

26 August 2024

1 reference

4 December 2017

volume

28 Suppl 6

1 reference

4 December 2017

page(s)

G3-13

1 reference

Invasive disease due to nontypeable Haemophilus influenzae among children in Arkansas

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Epidemiological differences among pneumococcal serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Cost Effectiveness of Pneumococcal Vaccination for Infants and Children with the Conjugate Vaccine PnC-7 in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Invasive pneumococcal infections in Canadian children, 1991-1998: implications for new vaccination strategies. Canadian Paediatric Society/Laboratory Centre for Disease Control Immunization Monitoring Program, Active (IMPACT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Bacterial otitis media: a vaccine preventable disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Pneumococcal disease in western Europe: burden of disease, antibiotic resistance and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Changes in frequency and pathogens causing acute otitis media in 1995-2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Current face of acute otitis media: microbiology and prevalence resulting from widespread use of heptavalent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Multinational study of pneumococcal serotypes causing acute otitis media in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Changing Epidemiology of Invasive Pneumococcal Disease in Canada, 1998–2007: Update from the Calgary‐Area Streptococcus pneumoniae Research (CASPER) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Invasive pneumococcal infections in Canadian children, 1998-2003: implications for new vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Epidemiological and economic burden of pneumococcal diseases in Canadian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Cost-effectiveness of universal pneumococcal vaccination for infants in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

How to compare the efficacy of conjugate vaccines to prevent acute otitis media?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conju

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.013

7 January 2021

Haemophilus influenzae

series ordinal

27

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2010.06.013

26 August 2024

Identifiers

1 reference

4 December 2017

1 reference